In our first episode, we're shining a light on the next frontier for outcomes-based agreements (OBA). If we move beyond the initial excitement and PR, where does pharma stand on risk-sharing and innovative contracting?
Experts
Roman Casciano, GM, Analytica Laser & SVP, Market Access, HEOR and Real-world Evidence, Certara
Lee Stern, VP, Business Development, Certara Evidence & Access
Ulrich Neumann, Sr. Director, Head US Access, Certara ([email protected])
---
Send in a voice message: https://podcasters.spotify.com/pod/show/market-access/message
Podden och tillhörande omslagsbild på den här sidan tillhör Certara Evidence & Access. Innehållet i podden är skapat av Certara Evidence & Access och inte av, eller tillsammans med, Poddtoppen.
